netFormulary Joint Medicines Formulary NHS
Airedale NHS Foundation Trust
Airedale, Wharfedale and Craven CCG
 
 Search
 Results

Looking for Adalimumab found 35 matches

Formulary items 2 matches
   
Formulary BNF Category
  Restricted Drug  Adalimumab Drugs affecting the immune response - 10.01.03
  Restricted Drug  Adalimumab Subcutaneous Injection  (Humira, Amgevita) Cytokine inhibitors - 01.05.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) (01.05.03)
link in drug section NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) (01.05.03)
link in drug section NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) (01.05.03)
link in drug section NICE TA143: Adalimumab, etanercept and infliximab for ankylosing spondylitis [May 2008] (10.01.03)
link in drug section NICE TA143: Adalimumab, etanercept and infliximab for ankylosing spondylitis [May 2008] (10.01.03)
link in drug section NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (May 2010) (01.05.03)
link in drug section NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (May 2010) (01.05.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [August 2010] (10.01.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [August 2010]  (10.01.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [August 2010] (10.01.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis [August 2010] (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab [August 2010] (10.01.03)
link in drug section NICE TA199:Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis [August 2010] (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015) (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015) (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015) (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015) (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (Januray 2016) (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (10.01.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (July 2017) (10.01.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (July 2017) (10.01.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (July 2017) (10.01.03)
link in drug section NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (July 2017) (01.05.03)
link in drug section NICE TA460:Adalimumab and dexamethasone for treating non-infectious uveitis (July 2017) (11.04.01)


 

netFormulary